Detected ·
Nouscom
€120MSeries D
Nouscom announced a €120M ($135M) oversubscribed Series D to advance NOUS209, an off-the-shelf cancer interception immunotherapy for Lynch Syndrome, into a pivotal global trial.
- Website
- —
- —
- Amount
- €120 000 000 EUR
- Stage
- Series D
- Event
- Funding round
- Detected
- 2026-10-19 12:01:37 UTC
- Signal ID
- dffaa6c8-f89f-48b8-8771-844bd4565bfb
As the API returns it
{
"id": "dffaa6c8-f89f-48b8-8771-844bd4565bfb",
"created_at": "2026-10-19T12:01:37.049638Z",
"company_name": "Nouscom",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": 120000000,
"funding_currency": "EUR",
"funding_stage": "series_d",
"message": "*Nouscom announced a €120M ($135M) oversubscribed Series D to advance NOUS209, an off-the-shelf cancer interception immunotherapy for Lynch Syndrome, into a pivotal global trial.*"
}